1. Loblaw DA, Mendelson DS, Talcott JA et al. American Society of Clinical Oncology. American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Clin Oncol 2004; 22(14): 2924-2941.
2. Mcleod DG. Hormonal therapy: historical perspective to future directions. Urology 2003; 61(2, Suppl 1): 3-7.
3. Abbas F, Scardino PT. Why neoadjuvant androgen deprivation prior to radical prostatectomy in unnecessary. Urol Clin North Am 1996; 23(4): 587-604.
4. Teillac P. Is there a place for neoadjuvant hormonal therapy before radical prostatectomy or radiation therapy in the management of prostate cancer? Prostate Cancer Prostatic Dis 1999; 2(Suppl 2): S8-S11.
5. EAU Guidelines for prostate cancer, March 2005.
6. See WA. Adjuvant hormone therapy after radiation or surgery for localized or locally advanced prostate cancer. Curr Treat Options Oncol 2003;4(5): 351-362.
7. Messing EM, Manola J, Sarosdy M et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999; 341: 1781-1788.
8. Messing EM, Manola J, Sarosdy M et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. Results at 10 years of EST 3886. J Urol 2003; 169(Suppl): 196 (Abs. 1480).
9. Zincke H, Lau W, Bergstralh E, Blute ML. Role of early adjuvant hormonal therapy after radical prostatectomy for prostate cancer. J Urol 2001; 166(6): 2208-2215.
10. Pilepich MV, Krall JM, Al-Sarraf M et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. Urology 1995; 45: 616-623.
11. Pilepich MV, Winter K, John MJ et al. Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001; 50: 1243-1252.
12. Bolla M, Gonzales D, Warde P et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997; 337: 295-300.
13. Bolla M, Gonzales D, Warde P et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002; 360: 103-108.
14. Zimmerman RA, Culkin DJ. Clinical strategies in the management of biochemical recurrence after radical prostatectomy. Clin Prostate Cancer 2003; 2: 160-166.
15. Khan MA, Partin AW. Management of patients with an increasing prostate-specific antigen after radical prostatectomy. Curr Urol Rep 2004; 5: 179-187.
16. Pound CR, Partin AW, Eisenberger MA et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: 1591-1597.
17. Schroder FH. Endocrine treatment of prostate cancer-recent developments and the future. Part I: maximal androgen blockade, early vs delayed endocrine treatment and side-effect. BJU Int 1999; 83: 161-170.
18. Moul JW. Prostate specific antigen only progression of prostate cancer. J Urol 2000; 163: 1632-1642.
19. Khan MA, Partin AW: Management of high-risk populations with locally advanced prostate cancer. Oncologist 2003; 8(3): 259-269.
20. Moul JW. Contemporary hormonal management of advanced prostate cancer. Oncology (Huntingt) 1998; 12(4): 499-505.
21. Auclerc G, Antoine EC, Cajfinger F et al. Management of advanced prostate cancer. Oncologist 2000; 5(1): 36-44.
22. Kaisary AV, Tyrrell CJ, Peeling WB, Griffiths K. Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma. Br J Urol 1991; 67(5): 502-508.
23. Vogelzang NJ, Chodak GW, Soloway MS et al. Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Zoladex prostate Study Group. Urology 1995; 46(2): 220-226.
24. Seidenfeld J, Samson DJ, Hasselblad V et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review an meta-analysis. Am Intern Med 2004; 132(7): 566-577.
25. Parmar H, Edwards L, Philips RH et al. Orchiectomy versus long-acting D-Trp-6-LHRH in advanced prostatic cancer. Br J Urol 1987; 59(3): 248-254.
26. Chu FM, Jayson M, Dineen MK et al. A clinical study of 22.5 mg La-2550: A new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancer. J Urol 2002; 168(3): 1199-1203.
27. Heyns CF, Simonin MP, Grosgurin P et al. For the South African Triptorelin Study Group. Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer. BJU Int 2003; 92(3): 226-231.
28. Khan MS, O´Brien A. An evaluation of pharmacokinetics and pharmacodynamics of leuprorelin acetate 3M-depot in patients with advanced and metastatics carcinoma of the prostate. Urol Int 1998; 60(1): 33-40.
29. Fontana D, Mari M, Martinelli A et al. 3-month formulation of goserelin acetate (Zoladex 10.8 mg depot) in advanced prostate cancer. Results from an Italian, open multicenter trial. Urol Int 2003; 70(4): 316-320.
30. Sarosdy MF, Schellhammer PF, Soloway MS et al. Endocrine effect, efficacy and tolerability of a 10.8 mg depot formulation of goserelin acetate administered every 13 weeks to patients with advanced prostate cancer. BJU Int 1999; 83(7): 801-806.
31. Tombal B. Appropriate castration with luteinising hormone releasing hormone (LHRH) agonists: what is the optimal level of testosterone? Eur Urol Suppl 2005; 4(5): 14-19.
32. Perez-Marreno R, Chu FM, Gleason D et al. A six-month, open-label study assesing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancer. Clin Ther 2002; 24(11): 1902-1904.
33. Kienle E, Lubben G. Efficacy and safety of leuprorelin acetate depot for prostate cancer. The German Leuprorelin Study Group. Urol Int 1996; 56(Suppl): 23-30.
34. Jocham D. Leuprorelin three-month depot in the treatment of advanced and metastatic prostate cancer: long-term follow-up results. Urol Int 1998; 60(Suppl 2): 18-24.
35. Fernandez del Moral P, Dijkman GA, Debruyne FM et al. Three-month depot of goserelin acetate: clinical efficacy and endocrine profile. Dutch South east Cooperative Urological Group. Urology 1996; 48(6): 894-900.
36. Tyrell CJ, Altwein JE, Klippel F et al. Comparison of an LHRH analogue (Goserelin acetate Zoladex) with combined androgen blockade in advanced prostate cancer: final survival results of an international multicentre randomized trial. International Prostate Cancer Study Group. Eur Urol 2000; 37(2): 205-211.
37. Prostate Cancer Trialists Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomized trials with 3 283 deaths in 5 710 patients. Prostate Cancer Trialists Collaborative Group. Lancet 1995; 346(8970): 265-269.
38. Prostate Cancer Trialists Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomized trials. Prostate Cancer Trialists Collaborative Group. Lancet 1995; 355(9214): 1491-1498.
39. Schmidt B, Bennett C, Seidenfeld J et al. Maximum androgen blockade for advanced prostate cancer. The Cochrane database of systematic Reviews 2005.
40. Newling D. Advanced prostate cancer: immediate or deferred hormone therapy? Eur Urol 2001; 39(Suppl 1): 15-21.
41. Caubet JF, Tosteson TD, Dong EW et al. Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens. Urology 1997; 49(1): 71-78.
42. Rizzo M, Mazzei T, Mini E et al. Leuprorelin acetate depot in advanced prostatic cancer: a phase II multicentre trial. J Int Med Res 1990; 18(Suppl 1): 114-125.
43. Sharifi R, Knoll LD, Smith J, Kramolowsky E. Leuprolide acetate (30 mg depot every four months) in the treatment of advanced prostate cancer. Urology 1998; 51: 271-276.
44. The Leuprolide Study Group. Leuprolide versus diethylstilboestrol for metastatic prostate cancer. N Engl J Med 1984; 311: 1281-1286.
45. Fowler JE, Flanagan M, Gleason DM et al. For the VIADUR study Group. Evaluation of an implant that delivers Leuprolide for 1 year for the paliative treatment of prostate cancer. Urology 2000; 55: 639-642.
46. Oefelein MG, Resnick MI. Effective testosterone suppresion for patients with prostate cancer: is there a best castration? Urology 2003; 62(2): 207-713.
47. Oefelein MG, Feng A, Scolieri MJ et al. Reassessment of the definition of castrate levels of testosterone: Implications for clinical decision making. Urology 2000; 56(6): 1021-1024.
48. Zherdev AV, Byzova NA, Izumrudov VA, Dzantiev BB. Rapid polyelectrolyte-based immunofiltration technique for testosterone detection in serum samples. Analyst 2003; 128(10): 1275-1280.
49. Kaisary AV, Tyrell CJ, Peeling WB, Griffiths K. Comparison of LHRH analoque (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma. Br J Urol 1991; 67(5): 502-508.
50. Rohl HF, Beuke HP. Effect of orchiectomy on serum concentrations of testosterone and dihydrotestosterone in patients with prostatic cancer. Scand J Urol Nephrol 1992; 26(1): 11-14.
51. Lin BJ, Chen KK, Chen MT, Chang LS. The time for serum testosterone to reach castrate level after bilateral orchiectomy or oral estrogen in the management of metastatic prostatic cancer. Urology 1994; 43(6): 834-837.
52. Vogelzang NJ, Chodak GW, Soloway MS et al. Prostate Study Group. Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Urology 1995; 46(2): 220-226.
53. Oefelein MG, Cornum R. Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm. J Urol 2000; 164(3 Pt 1): 726-729.
54. Kawakami J, Morales A. A comprehensive hormonal evaluation in patients with cancer of the prostate on androgen supression with LHRH agonists. J Urol 2002; 167(Suppl 4): 288 (Abs. 1135).
55. Oefelein MG. Serum testosterone-based luteinizing hormone-releasing hormone agonist redosing schedule for chronic androgen ablation: a phase I assessment. Urology 1999; 54(4): 694-699.
56. Oefelein MG. Health related quality of life using serum testosterone as the trigger to re-dose long acting depot luteinizing hormone-releasing hormone agonists in patient with prostate cancer. J Urol 2003; 169(1): 251-255.
57. Hall MC, Fritzsch RJ, Sagalowsky AI et al. Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer. Urology 1999; 53(5): 898-902.
58. Gommersall LM, Hayne D, Shergill IS et al. Luteinising hormone releasing hormone analoques in the treatment of prostate cancer. Expert Opin Pharmacother 2002; 3: 1685-1692.
59. Chu FM, Jayson M, Dineen MK et al. A clinical study of 22.5 mg LA-2550: a new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancer. J Urol 2002; 168: 1199-1203.
60. Perez Marreno R, Chu FM, Gleason D et al. A six-month open label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancer. Clin Ther 2002; 24: 1902-1914.
61. Oefelein MG, Resnick MI. Effective testosterone suppression for patients with prostate cancer: is there a best castration? Urology 2003; 62: 207-221.
62. Kawakami J, Morales A, Kingston ON. A comprehensive evaluation in patients with cancer of the prostate on androgen suppression with LHRH agonists. J Urol 2002; 176: 288 (Abs. 1135).
63. Perez Mareno R, Tyler RC. A subcutaneous delivery system for the extended release of leuprolide acetate for the treatment of prostate cancer. Expert Opin Pharmacother 2004; 5: 447-457.
64. Nishiyama T, Kanazawa S, Watanabe R et al. Influence of hot flashes on quality of life in patients with prostate cancer treated with androgen deprivation therapy. Int J Urol 2004; 11: 735-741.